It's "certainly clear that there will be negative impact going forward," but one analyst said the stock has already seen the worst.
Jim Cramer spoke with Allergan CEO Brent Saunders on why the company will not engage in price gouging, and its latest acquisitions.
Jim Cramer shares his take on various caller stocks, including this pharma stock caught in the political pricing war.
Jim Cramer says the lack of common ground between Hillary Clinton and Donald Trump is causing uncertainty in the market.
After turning down Mylan's $26B offer, shares of Perrigo have lost almost half their value.
CNBC's Meg Tirrell reports the latest on the response from EpiPen maker Mylan to Sen. Chuck Grassley's inquiries over the controversial price hike for the drug.
The only way to stop drug companies from jacking up the costs of live-saving treatments is through price controls, a former Obama health advisor says.
Some are questioning whether Mylan's generic EpiPen may net the drugmaker more revenue than the original version.
There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC.
CNBC's Meg Tirrell reports on the fears in the biotech market following the Mylan EpiPen pricing saga, as well as the news that Mylan will launch a generic EpiPen auto-injector.
Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
Shares of Teva Pharmaceuticals fell as much as 6 percent after the U.S. Patent Office invalidated two of the company's patents.
Umer Raffat, Evercore ISI Senior Analyst, discusses how Mylan's stock price may be affected long-term by the EpiPen pricing saga.
Heather Bresch is the daughter of a U.S. senator, incorporated her American company in the Netherlands and got an MBA she wasn't entitled to.
Shares of Teva Pharmaceutical Industries are plunging, as U.S. patent offices invalidated their drug patent. CNBC's Meg Tirrell reports.
Three U.S. senators are slamming the $24 billion drug firm for jacking up the cost of its anaphylaxis treatment more than fivefold since 2008.
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent.
The "FMHR" traders and Stephanie Link, TIAA Global Asset Management, discuss Mylan's EpiPen pricing saga and whether it's a new catalyst to sell Biotech.
Mylan has increased the price of the anti-allergy device EpiPen more than five-fold in recent years.